Dawn W Langdon
Overview
Explore the profile of Dawn W Langdon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
379
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bakirtzis C, Langdon D, Grigoriadis N
Ann Neurol
. 2023 Mar;
93(5):1040.
PMID: 36891629
No abstract available.
2.
Langdon D, Tomic D, Penner I, Calabrese P, Cutter G, Haring D, et al.
Eur J Neurol
. 2021 Aug;
28(12):4135-4145.
PMID: 34431170
Background And Purpose: Studies reporting the baseline determinants of cognitive performance and treatment effect on cognition in patients with multiple sclerosis (MS) are limited. We investigated the baseline correlates of...
3.
Reen G, Silber E, Langdon D
Mult Scler Relat Disord
. 2021 Jan;
49:102737.
PMID: 33513520
Background: Multiple Sclerosis (MS) patients find it difficult to understand the complex risk-benefit profiles of disease-modifying drugs. An evidence-based protocol was designed to improve patient's understanding of treatment information: Benefit...
4.
Betscher E, Guenter W, Langdon D, Bonek R
Neurol Neurochir Pol
. 2020 Oct;
55(1):59-66.
PMID: 33047783
Background: Cognitive impairment is recognised as a significant clinical issue in Multiple Sclerosis (MS). It can occur at any stage of the disease, affecting quality of life, occupational activity, and...
5.
Reen G, Silber E, Langdon D
Value Health
. 2018 Jul;
21(7):762-766.
PMID: 30005747
Background: Patients' understanding of treatment risks and benefits is a prerequisite for shared decision making. Yet, patients with multiple sclerosis (MS) do not accurately understand treatment information provided in regular...
6.
7.
Reen G, Silber E, Langdon D
J Neurol Sci
. 2017 Mar;
375:107-122.
PMID: 28320112
Background: Multiple sclerosis (MS) patients are faced with complex risk-benefit profiles of disease-modifying drugs (DMDs) when making treatment decisions. For effective shared decision-making, MS patients should understand the risks and...
8.
Reen G, Silber E, Langdon D
Patient Educ Couns
. 2017 Jan;
100(6):1031-1048.
PMID: 28108125
Objective: The present review evaluates interventions that have been designed to improve understanding of the complex risk-benefit profiles of disease-modifying drugs (DMDs) in patients with Multiple Sclerosis (MS). Methods: A...
9.
Sandi D, Rudisch T, Fuvesi J, Fricska-Nagy Z, Huszka H, Biernacki T, et al.
Mult Scler Relat Disord
. 2015 Nov;
4(6):499-504.
PMID: 26590654
Background: Multiple Sclerosis (MS) causes not only somatic, but also cognitive impairment regardless of the patients׳ age or the course of the disease. The Brief International Cognitive Assessment for MS...
10.
Langdon D
Curr Opin Neurol
. 2011 Apr;
24(3):244-9.
PMID: 21519256
Purpose Of Review: A broad overview of cognition in multiple sclerosis (MS) is provided, taking account of its impact on the lives of patients, how cognitive impairment relates to disease...